Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 3/20 | 0.38 |
| ▸ | SKP1 | P63208 | 3/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | BPTF | Q12830 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23304587 | 0.88 | HRH4 (0.41) | MAPT | |
| SCHEMBL23304383 | 0.87 | NPC1 (0.41) | GBA1NPC1RAB9ACKS1BSKP1 | |
| SCHEMBL23684405 | 0.87 | MAP4K4 (0.39) | GBA1NPC1RAB9ACKS1BSKP1 | |
| SCHEMBL30260122 | 0.86 | GBA1 (0.43) | GBA1CKS1BSKP1SKP2GPR119 | |
| SCHEMBL23684218 | 0.86 | GBA1 (0.43) | GBA1CKS1BSKP1SKP2GPR119 | |
| SCHEMBL30260181 | 0.86 | HTR2A (0.40) | GBA1NPC1RAB9ACKS1BSKP1 | |
| SCHEMBL23304303 | 0.86 | HTR2A (0.40) | GBA1NPC1RAB9ACKS1BSKP1 | |
| SCHEMBL23304666 | 0.84 | HRH3 (0.37) | KCNH2GPR119 | |
| SCHEMBL1579584 | 0.83 | KCNH2 (0.47) | CKS1BSKP1SKP2KCNH2MAP4K4 | |
| SCHEMBL23304301 | 0.82 | GBA1 (0.49) | GBA1NPC1RAB9ACKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403137-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2021086879-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021086879-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | GBA1 232/4885NPC1 209/4885RAB9A 1533/4885 |
| US-12403137-B2 | Compounds and methods of use | XDH, LPXN, F12 | GBA1 374/4885NPC1 273/4885RAB9A 2062/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | GBA1 232/4885NPC1 209/4885RAB9A 1533/4885 |
| US-20230054084-A1 | COMPOUNDS AND METHODS OF USE | XDH, LPXN, F12 | GBA1 374/4885NPC1 273/4885RAB9A 2062/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | GBA1 232/4885NPC1 209/4885RAB9A 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.